Nanosponges attract coronavirus away from lung cells, study shows

Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories (NEIDL) and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.

The breakthrough technology could have major implications for fighting the SARS-CoV-2 virus responsible for the global pandemic that's already claimed nearly 450,000 lives and infected more than 8 million people. But, perhaps even more significantly, it has the potential to be adapted to combat virtually any virus, such as influenza or even Ebola.

I was skeptical at the beginning because it seemed too good to be true. But when I saw the first set of results in the lab, I was just astonished."

Anna Honko, NEIDL microbiologist, one of the co-first authors on the study

The technology consists of very small, nanosized drops of polymers--essentially, soft biofriendly plastics--covered in fragments of living lung cell and immune cell membranes.

In cell culture studies at BU’s National Emerging Infectious Diseases Laboratories, nanosponges containing fragments of lung cell membranes attracted and fused with the SARS-CoV-2 virus responsible for COVID-19 infections, preventing the coronavirus from infecting living lung cells. Photo courtesy of the Griffiths lab/BU NEIDL

"It looks like a nanoparticle coated in pieces of cell membrane," Honko says. "The small polymer [droplet] mimics a cell having a membrane around it."

The SARS-CoV-2 virus seeks out unique signatures of lung cell membranes and latches onto them. When that happens inside the human body, the coronavirus infection takes hold, with the SARS-CoV-2 viruses hijacking lung cells to replicate their own genetic material. But in experiments at the NEIDL, BU researchers observed that polymer droplets laden with pieces of lung cell membrane did a better job of attracting the SARS-CoV-2 virus than living lung cells.

By fusing with the SARS-CoV-2 virus better than living cells can, the nanotechnology appears to be an effective countermeasure to coronavirus infection, preventing SARS-CoV-2 from attacking cells.

"Our guess is that it acts like a decoy, it competes with cells for the virus," says NEIDL microbiologist Anthony Griffiths, co-corresponding author on the study. "They are little bits of plastic, just containing the outer pieces of cells with none of the internal cellular machinery contained inside living cells. Conceptually, it's such a simple idea. It mops up the virus like a sponge."

That attribute is why the UC San Diego and BU research team call the technology "nanosponges." Once SARS-CoV-2 binds with the cell fragments inside a nanosponge droplet--each one a thousand times smaller than the width of a human hair--the coronavirus dies. Although the initial results are based on experiments conducted in cell culture dishes, the researchers believe that inside a human body, the biodegradable nanosponges and the SARS-CoV-2 virus trapped inside them could then be disposed of by the body's immune system. The immune system routinely breaks down and gets rid of dead cell fragments caused by infection or normal cell life cycles.

There is also another important effect that the nanosponges have in the context of coronavirus infection. Honko says nanosponges containing fragments of immune cells can soak up cellular signals that increase inflammation. Acute respiratory distress, caused by an inflammatory cascade inside the lungs, is the most deadly aspect of the coronavirus infection, sending patients into the intensive care unit for oxygen or ventilator support to help them breathe.

But the nanosponges, which can attract the inflammatory molecules that send the immune system into dangerous overdrive, can help tamp down that response, Honko says. By using both kinds of nanosponges, some containing lung cell fragments and some containing pieces of immune cells, she says it's possible to "attack the coronavirus and the [body's] response" responsible for disease and eventual lung failure.

At the NEIDL, Honko and Griffiths are now planning additional experiments to see how well the nanosponges can prevent coronavirus infection in animal models of the disease. They plan to work closely with the team of engineers at UC San Diego, who first developed the nanosponges more than a decade ago, to tailor the technology for eventual safe and effective use in humans.

"Traditionally, drug developers for infectious diseases dive deep on the details of the pathogen in order to find druggable targets," said Liangfang Zhang, a UC San Diego nanoengineer and leader of the California-based team, according to a UC San Diego press release. "Our approach is different. We only need to know what the target cells are. And then we aim to protect the targets by creating biomimetic decoys."

When the novel coronavirus first appeared, the idea of using the nanosponges to combat the infection came to Zhang almost immediately. He reached out to the NEIDL for help. Looking ahead, the BU and UC San Diego collaborators believe the nanosponges can easily be converted into a noninvasive treatment.

"We should be able to drop it right into the nose," Griffiths says. "In humans, it could be something like a nasal spray."

Honko agrees: "That would be an easy and safe administration method that should target the appropriate [respiratory] tissues. And if you wanted to treat patients that are already intubated, you could deliver it straight into the lung."

Griffiths and Honko are especially intrigued by the nanosponges as a new platform for treating all types of viral infections. "The broad spectrum aspect of this is exceptionally appealing," Griffiths says. The researchers say the nanosponge could be easily adapted to house other types of cell membranes preferred by other viruses, creating many new opportunities to use the technology against other tough-to-treat infections like the flu and even deadly hemorrhagic fevers caused by Ebola, Marburg, or Lassa viruses.

"I'm interested in seeing how far we can push this technology," Honko says.